49 completed, 8 unknown, 2 terminated, 1 withdrawn. 17 Phase 2, 15 Phase 3, 11 Phase 1, 9 Phase 4, 7 Not applicable.
Follow Nasal Sprays: new trials by email Literature Review of Nasal Sprays trials Research Report on Nasal Sprays
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy Study of Dexmedetomidine Nasal Spray Combined With Propofol for Deep Sedation in ERCP Dexmedetomidine Injection (nasal spray) + Propofol Injection + Sufentanil Injection, Normal Saline (nasal spray) + Dexmedetomidine Injection (intravenous) + Propofol Injection + Sufentanil Injection, Regular sedation protocol - Dexmedetomidine Induced Sedation, Nasal Administration | Not applicable | Completed | Shiyou Wei | 180 | 2025-10-02 | 2025-11-28 |
| Feasibility, Acceptability, and Safety of a Drug-Free Nasal Spray in Frontline Healthcare Workers Nasal Spray - Healthy Adults | Not applicable | Completed | Akita Biosciences, Inc. | 127 | 2025-02-26 | 2026-10-22 |
| The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus COVID-19 vaccine, low dose level, COVID-19 vaccine, high dose level, Nasal Drops - COVID19, Sars-Cov-2 | Phase 1 | Completed | Rokote Laboratories Finland Oy | 40 | 2025-01-21 | 2025-12-08 |
| Azelastine Allergen Chamber - Onset of Action Study Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair), Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray, Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray - Seasonal Allergic Rhinitis | Phase 2 | Completed | MEDA Pharma GmbH & Co. KG | 84 | 2023-10-30 | 2024-03-20 |
| Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis. Azelastine + Mometazone, nasal spray, Momat Rhino Advance - Seasonal Allergic Rhinitis | Phase 3 | Completed | Sandoz | 472 | 2023-02-13 | 2023-08-04 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease Varenicline Tartrate Nasal Spray - Dry Eye Disease | Phase 1 | Completed | Corxel Pharmaceuticals | 9 | 2022-12-07 | 2023-05-01 |
| Intranasal Steroid as Medical Therapy For Sleep-Disordered Breathing in Children Mometasone Furoate 50mcg Nasal Spray, Sodium Chloride 0.9 % Nasal Spray - Sleep Disorder; Breathing-Related, Snoring | Phase 4 | Completed | Murdoch Childrens Research Institute | 130 | 2022-12-05 | 2025-09-30 |
| Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray, Mometasone Nasal Irrigation (1 mg capsule), Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation - Chronic Rhinitis | Phase 4 | Unknown | Endeavor Health | 81 | 2022-11-23 | 2023-07-28 |
| Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III Chlorpheniramine Maleate 0.4% Nasal Spray, Placebo - COVID-19, Symptoms and Signs | Phase 2 / Phase 3 | Completed | Dr. Ferrer BioPharma | 157 | 2022-07-27 | 2023-06-02 |
| Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Varenicline Tartrate Nasal Spray, Placebo (vehicle) - Dry Eye Disease | Phase 3 | Completed | Corxel Pharmaceuticals | 340 | 2022-07-22 | 2023-04-25 |
| Inhaled vs Intranasal Corticosteroids for Chronic Cough in Upper Airway Cough Syndrome Budesonide (400μg/d), Mometasone Furoate 50mcg Nasal Spray - Chronic Cough (CC), Upper Airway Cough Syndrome | Not applicable | Completed | Silesian University of Medicine | 56 | 2022-07-01 | 2026-09-16 |
| Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists Narcan 40 MG/ML Nasal Spray, Naloxone Hydrochloride, Nalmefene HCl injection - Opioid Induced Respiratory Depression, Chronic Opioid Use | Phase 1 | Terminated | Leiden University Medical Center | 58 | 2022-06-24 | 2026-07-29 |
| Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI 56mg esketamine (2x Spravato® 28 mg nasal spray), 0.9% saline solution nasal spray - Ketamine Treatment | Phase 1 | Completed | Rupert Lanzenberger | 33 | 2022-06-01 | 2024-04-15 |
| The Role of Nasal Breathing for Perfomance in Elite Athletes. Oxymetazoline, 0.05% Nasal Spray - Breathing, Mouth | Not applicable | Completed | Sahlgrenska University Hospital | 12 | 2022-01-13 | 2024-07-01 |
| Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2 Nasal Spray - Covid19 | Phase 3 | Withdrawn | Larkin Community Hospital | 2021-12-08 | 2023-10-16 | |
| Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I Chlorpheniramine Maleate 1% Nasal Spray, Placebo - COVID-19, Symptoms and Signs | Phase 2 / Phase 3 | Completed | Dr. Ferrer BioPharma | 101 | 2021-12-07 | 2023-03-23 |
| OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers OC-01 (varenicline 0.6mg/ml) Nasal Spray, Placebo (vehicle) nasal spray - Dry Eye | Phase 4 | Completed | Center for Ophthalmic and Vision Research, LLC | 75 | 2021-12-03 | 2022-11-03 |
| IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray - Dry Eye Disease | Phase 2 | Unknown | Vance Thompson Vision - MT | 20 | 2021-12-01 | 2021-11-30 |
| Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection Nitric Oxide, Nasal spray with isotonic saline - SARS-CoV-2 Infection | Phase 3 | Terminated | Sanotize Research and Development corp. | 1389 | 2021-11-20 | 2025-09-25 |
| Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19 Nitric Oxide - SARS-CoV-2 Infection | Phase 3 | Completed | Sanotize Research and Development corp. | 306 | 2021-11-01 | 2022-10-31 |
Showing 20 of 60. Sign in to see all of them.
Dry Eye Syndromes (12) · COVID-19 (7) · Rhinitis, Allergic, Seasonal (7) · Rhinitis, Allergic, Perennial (4) · Migraine Disorders (3) · Rhinitis, Allergic (3) · Coronavirus Infections (2) · Osteoporosis (2) · Rhinitis (2) · Signs and Symptoms (2) · Bone Diseases, Metabolic (1) · Chronic Cough (1) · Crowding (1) · Epilepsy (1) · Headache (1)
Oyster Point Pharma, Inc. (9) · Alcon Research (3) · Dr. Ferrer BioPharma (3) · Archimedes Development Ltd (2) · Corxel Pharmaceuticals (2) · GlaxoSmithKline (2) · Sanotize Research and Development corp. (2) · Sumitomo Pharma America, Inc. (2) · Tarsa Therapeutics, Inc. (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Acorda Therapeutics (1) · Akita Biosciences, Inc. (1) · Azelon Pharmaceuticals (1) · Brandon Baartman (1) · California Medical Clinic for Headache (1)
United States (31) · China (4) · United Kingdom (3) · Canada (2) · Honduras (2) · Switzerland (2) · Australia (1) · Austria (1) · Dominican Republic (1) · Finland (1) · France (1) · Germany (1) · India (1) · Jordan (1) · Mexico (1)
Keith Moore, PHARMD (2) · Thomas Legg, D.O. (2) · Alain Serrie, MD (1) · Brandon Baartman, MD (1) · Brian MacDonald (1) · Cort A Pedersen, M.D. (1) · David B Kudrow, MD (1) · David Squillacote, MD (1) · Don Kellerman, PharmD (1) · Gustavo Ferrer, MD (1)
PMID 37096956, PMID 36401081, PMID 19490626, PMID 24125150, PMID 24717794, PMID 25028522, PMID 29878341, PMID 30877622, PMID 34456060, PMID 34767866, PMID 34920097, PMID 35472193, PMID 35653029, PMID 35965109, PMID 36107843, PMID 36728653, PMID 37335995, PMID 40088395, PMID 40356464, PMID 41222549, PMID 41557344, PMID 41642634, PMID 41693798, PMID 42180735
2023 (1)